Catalyst biosciences, inc. (CBIO)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Operating Activities
Net loss

-55,178

-30,055

-21,561

-

-

-

-

-

-

-

-

Net loss

-

-

-

-16,945

-14,762

-6,613

-9,966

-6,998

-8,529

10,899

-39,404

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense

3,204

2,606

863

635

326

244

297

7,846

8,513

4,937

2,454

Recognition of deferred revenue

-

-

-

-

-

-

-

57,860

97,439

83,767

6,383

Amortization of premium on marketable securities, net

-

-

-

-

-

-

-

937

911

416

-

Depreciation and amortization

146

149

173

389

470

679

974

2,212

2,480

1,997

1,835

Non-cash interest expense

-

-

-

-

1,478

-

-

-

-

-

-

Excess tax benefits from stock-based compensation

-

-

-

-

-

-

-

-

-

3,503

41

Loss on disposal of property and equipment

-

-116

-18

-

-15

-77

-

55

-

-

-

Loss on disposal of assets

-

-

-

2,231

-

-

-

-

-

-

-

Impairment of patent assets

-

-

-

-

-

53

-

-

-

-

-

Gain on extinguishment of redeemable convertible notes

-

-

-

99

52

-

-

-

-

-

-

Change in fair value of warrant liability

-

-

-

-

-91

-354

-

-

-

-

-

Change in fair value of derivative liability

-

-

-

1,057

242

-

-

-

-

-

-

Income tax expense from other comprehensive income

-

-

-

-

-

-

-

-101

-

-

-

Changes in operating assets and liabilities:
Accounts receivable

15,000

-

-7

-461

79

-1

51

-

-

-

-

Prepaid and other current assets

490

2,895

351

-956

1,350

-98

-53

-

-

-

-

Deposits

-

-

128

-

-

-

-

-

-

-

-

Accounts payable

3,031

500

-90

-102

-4,273

-105

11

-

-

-

-

Accrued compensation and other accrued liabilities

5,599

850

1,287

-60

1,150

-2

-246

-

-

-

-

Operating lease liability and right-of-use asset

75

-

-

-

-

-

-

-

-

-

-

Deferred revenue

15,000

-6

-118

-

-

-

-

-

-

-

-

Deferred rent

-

-182

40

19

-41

156

138

-

-

-

-

Proceeds from the reverse merger

-

-

-

-

23,931

-

-

-

-

-

-

Proceeds from maturities of investments

-

-

-

-

13,823

-

-

-

-

-

-

Net cash flows used in operating activities

-43,613

-28,553

-19,940

-

-

-

-

-

-83,718

138,298

-24,271

Investing Activities
Current receivables

-

-

-

-

-

-

-

1,162

-620

-

-

Other assets

-

-

-

-

-

-

-

-2,017

-

-

-

Receivables from collaborations

-

-

-

-

-

-

-

-

-

-200,963

-272

Other assets

-

-

-

-

-

-

-

-

443

1,815

28

Accounts payable and accrued expenses

-

-

-

-

-

-

-

-11,515

4,419

-3,802

16,551

Deferred revenue

-

-

-

-400

-1,749

-312

2,791

440

5,750

11,973

473

Net cash flows used in operating activities

-

-

-

-18,472

-19,118

-6,389

-6,273

-64,239

-

-

-

Proceeds from maturities of short-term investments

157,433

127,967

14,300

10,002

-

-

-

-

-

-

-

Purchase of short-term investments

129,977

198,912

25,472

-

-

-

-

-

-

-

-

Purchase of investments

-

-

-

13,401

-

-

-

120,972

156,253

144,012

31,000

Proceeds from sale of assets

-

-

-

1,674

-

-

-

-

-

-

-

Change in restricted cash

-

-

-

5

125

-

-

-

-

-

-

Proceeds from sale of investments in marketable securities

-

-

-

-

-

-

-

159,538

100,012

-

-

Proceeds from sale of property and equipment

-

-

-

890

0

98

-

1,589

5

43

-

Proceeds from sale of investments in marketable securities

-

-

-

-

-

-

-

-

-

-84,481

-41,000

Purchases of property and equipment

64

376

23

468

272

-

41

333

1,431

3,311

200

Net cash flows provided by investing activities

27,392

-71,321

-11,195

-

-

-

-

-

-57,667

-62,799

9,800

Financing Activities
Net cash flows provided by investing activities

-

-

-

-1,308

37,357

98

-41

39,822

-

-

-

Release of restricted cash due to conversion and redemption of redeemable convertible notes

-

-

-

14,330

3,255

-

-

-

-

-

-

Payments for the redemption of redeemable convertible notes

-

5,082

14,318

14,340

3,020

-

-

-

-

-

-

Issuance of common stock for secondary public offering, net of issuance costs

-

106,762

-

-

-

-

-

-

-

-

-

Issuance of common stock from stock grants and option exercises

327

107

-

-

-

-

-

-

-

-

-

Proceeds from issuance of long-term debt

-

-

-

-

-

-

-

-

2,132

1,228

-

Principal payments on long-term debt

-

-

-

-

-

-

-

1,240

1,964

1,577

1,390

Excess tax benefits from stock-based compensation

-

-

-

-

-

-

-

-

-

3,503

41

Proceeds from issuance of common stock, net of issuance costs

-

-

5,336

958

-

-

-

614

82,646

3,292

48,527

Proceeds from issuance of preferred stock, common stock and warrants for follow-on offering, net of issuance costs

-

-

18,563

-

-

-

-

-

-

-

-

Proceeds from issuance of convertible preferred stock, net of issuance costs

-

-

-

-

7,259

4,981

5,742

-

-

-

-

Proceeds from issuance of convertible notes to related parties

-

-

-

-

1,888

-

-

-

-

-

-

Repurchase of common stock in connection with equity award assumed

-

-

-

-

82

-

-

-

-

-

-

Proceeds from exercise of stock options

-

-

-

-

13

25

-

-

-

-

-

Proceeds from exercise of warrants

-

9,545

1,817

-

-

-

-

-

-

-

-

Net cash flow provided by financing activities

327

111,332

21,082

-

-

-

-

-

82,814

6,446

47,178

Net cash flow provided by (used in) financing activities

-

-

-

948

9,313

5,006

5,742

-626

-

-

-

Net increase (decrease) in cash, cash equivalents and restricted cash

-15,894

11,458

-10,053

-

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

-

-

-

-18,832

27,552

-1,284

-573

-25,043

-58,571

81,945

32,707

Supplemental Disclosure of Non-Cash Investing and Financing Activities:
Deemed dividend for convertible preferred stock beneficial conversion feature

-

-

3,951

-

-

-

-

-

-

-

-

Adoption of ASC 606

-

207

-

-

-

-

-

-

-

-

-

Conversion of redeemable convertible notes to common stock

-

3

-

-

-

-

-

-

-

-

-

Investment securities received from the reverse merger

-

-

-

-

17,223

-

-

-

-

-

-

Redeemable convertible notes assumed upon reverse merger

-

-

-

-

37,073

-

-

-

-

-

-

Unrealized gain on investments

-

-

1

-2

1

-

-

-

-

-

-

Right-of-use asset and operating lease liability recorded upon the adoption of ASC 842, net

2,052

-

-

-

-

-

-

-

-

-

-

Embedded derivative related to redeemable convertible notes

-

-

-

-

1,455

-

-

-

-

-

-

Follow-on Offering
Proceeds from issuance of common stock, net of issuance costs

-

-

9,684

-

-

-

-

-

-

-

-